Branaplam - Novartis

Drug Profile

Branaplam - Novartis

Alternative Names: LMI 070; NVS-SM1

Latest Information Update: 09 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Cyclohexanes; Pyrazoles; Pyridazines; Small molecules
  • Mechanism of Action Survival of motor neuron 2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Spinal muscular atrophy

Most Recent Events

  • 08 Sep 2017 Chemical structure information added
  • 05 Sep 2017 Phase-I/II development is ongoing in Spinal muscular atrophy (In infants) in Belgium, Denmark, Germany and Italy (NCT02268552)
  • 27 Oct 2014 Preclinical trials in Spinal muscular atrophy in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top